With Measles Expected to Become an Endemic, This Growing Biotech Firm is Testing a Drug to Combat it!
Measles is likely to become endemic in the USA, according to modeling conducted by Stanford scientists (https://med.stanford.edu/news/all-news/2025/04/measles-vaccination.html).
The model primarily bases this conclusion on the declining rates of measles vaccination in the USA, especially since the COVID-19 pandemic. If the vaccination rates continue to decline, measles virus could become endemic, that is circulating in the population, within a few years.
This NYSE traded biotech is a clinical-stage global leader in developing revolutionary broad-spectrum antiviral drugs, believes it has a drug that is VERY likely to be affective against the measles virus!
The company’s NV-387 is a first-ever broad-spectrum antiviral that is capable of attacking over 90-95% of human pathogenic viruses; and that includes paramyxoviruses such as RSV and Measles virus.
The company has acquired the Measles virus and has completed growing the virus in the small quantities required for conducting an animal model study. This means they can now determine how effective NV-387 would be against the Measles virus! Management is highly enthused to perform this study by the fact that NV-387 was able to cure lethal lung infection by the related RSV in an animal model.
There is currently no drug for RSV or for Measles, and NV-387 could work against both viruses!"
With a revolutionary antiviral drug, see how this NYSE traded biotech is in a great position to build shareholder value as it goes after killer viruses!
